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Abstract
Sirtuin 6 (SIRT6) is a member of the NAD+-dependent class III deacetylase sirtuin family, which plays a key role in
cancer by controlling transcription, genome stability, telomere integrity, DNA repair, and autophagy. Here we analyzed
the molecular and biological effects of UBCS039, the first synthetic SIRT6 activator. Our data demonstrated that
UBCS039 induced a time-dependent activation of autophagy in several human tumor cell lines, as evaluated by
increased content of the lipidated form of LC3B by western blot and of autophagosomal puncta by microscopy
analysis of GFP-LC3. UBCS039-mediated activation of autophagy was strictly dependent on SIRT6 deacetylating activity
since the catalytic mutant H133Y failed to activate autophagy. At the molecular level, SIRT6-mediated autophagy was
triggered by an increase of ROS levels, which, in turn, resulted in the activation of the AMPK-ULK1-mTOR signaling
pathway. Interestingly, antioxidants were able to completely counteract UBCS039-induced autophagy, suggesting that
ROS burst had a key role in upstream events leading to autophagy commitment. Finally, sustained activation of SIRT6
resulted in autophagy-related cell death, a process that was markedly attenuated using either a pan caspases inhibitor
(zVAD-fmk) or an autophagy inhibitor (CQ). Overall, our results identified UBCS039 as an efficient SIRT6 activator,
thereby providing a proof of principle that modulation of the enzyme can influence therapeutic strategy by enhancing
autophagy-dependent cell death.
Introduction
Sirtuins are histone deacetylase enzymes that use
nicotinamide adenine dinucleotide (NAD+) as a co-
substrate for their enzymatic activities. They are mainly
involved in regulation of cell stress response and meta-
bolism, thus playing key roles in normal and cancer cells1.
Among the components of mammalian sirtuin family,
SIRT6 deacetylates the histone H3 on acetylated K9,
K562,3, and the more recently identified K18 and K27
residues4,5, causing the repression of many genes involved
in inflammation, aging, genome stability, metabolic
pathways, and telomere integrity2,6–8. Moreover, many
functions of SIRT6 are linked to its ability to deacetylate
and catalyze mono-ADP-ribosylation of non-histone
proteins, including transcription factors and other pro-
teins involved in DNA damage response, inflammation,
and immune response activation7,9–13. Due to its active
role in several important biological processes, SIRT6
dysregulation has been implicated in the onset of several
pathologies14,15. In cancer, the role of SIRT6 is con-
troversial14. In some tumors, SIRT6 acts as a tumor
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suppressor; indeed, SIRT6 expression has been found
downregulated in many human tumors (i.e. colorectal,
breast, ovarian, hepatocellular, lung, and pancreatic
tumors) and its downregulation is associated with poor
prognosis16–18. Consistent with these results, loss of
SIRT6 leads to tumor formation and maintenance8 and
ectopic expression of SIRT6 inhibits cancer stem cell
proliferation19,20. In other tumors (i.e. skin cancer, hepa-
tocarcinoma, multiple myeloma, and acute myeloid
leukemia), SIRT6 can act as a tumor promoter and
its overexpression has been associated to poor out-
comes21–23. Recent evidences reveal a role of sirtuins,
including SIRT6, in autophagy of several biological sys-
tems24–28. In normal cells, SIRT6-mediated induction of
autophagy is involved in oxidative stress-induced neuro-
nal damage29, bronchial epithelial cell senescence30, car-
diac hypertrophy26, and monocyte differentiation31. In
cancer, the role of SIRT6 in autophagic processes has
been poorly investigated. In particular, in esophageal
cancer cells, SIRT6 induces autophagy by activating ULK1
and inhibiting mTOR pathway21, while in melanoma it
differently affects tumor growth of primary and metastatic
tumors in an autophagy-dependent manner via the IGF-
AKT signaling pathway32.
Autophagy is a highly conserved multistep process that
is fundamental to maintain cellular homeostasis. During
this process, unfolded proteins or damaged organelles are
engulfed by double-membrane autophagosomes and are
delivered to lysosomes for degradation33. Defects in
autophagy have been associated with susceptibility to
genomic damage, metabolic stress, and, importantly,
tumorigenesis34. In recent years, an increasing number of
studies have provided a plethora of conflicting results
about the role of autophagy in cancer biology. Indeed, in
cancer cells, autophagy has a dual role, acting as a
mechanism of tumor suppression or as an adaptive stress
response to maintain tumor cell survival. Moreover, there
is a functional crosstalk between autophagy and apoptosis,
and either increased or blocked autophagic flux may
induce apoptotic cell death in various conditions35. To
date, there are only few modulators of the autophagic
pathway that have shown promising pharmacological
value36.
In this contest, exploiting the possibility to act on the
autophagic process, through a direct modulation of
SIRT6, could be of fundamental importance representing
a novel avenue in cancer therapy.
UBCS039 has been recently described as the first syn-
thetic activator of SIRT637. Here we explored the mole-
cular and biological effects of this compound in cancer
cell lines of different origin, including non-small cell lung,
colon and epithelial cervix carcinoma, and fibrosarcoma,
clearly demonstrating that pharmacological SIRT6 acti-
vation triggers an autophagy-related cell death.
Materials and methods
Cells and culture conditions
H1299 human non-small cell lung cancer, HT1080
human fibrosarcoma, HCT116 human colon, and HeLa
human epithelial cervix carcinoma cell lines were pur-
chased from American Type Culture Collection. HeLa
and HCT116 were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Euroclone, ECM0728L), H1299
and HT1080 in Roswell Park Memorial Institute medium
(RPMI 1640; Gibco, 21875–034), both supplemented with
10% fetal bovine serum. The indicated cell lines were
grown in a CO2 humidified incubator at 37 °C. HT1080
and H1299 cells were stably transfected with EGFP-LC3B
or mRFP-EGFP-LC3B fusion proteins as previously
reported38,39 and cultured in the presence of 800 μg/ml of
geneticin (G418 disulfate salt, Sigma-Aldrich, A1720).
Reagents
SIRT6 activator UBCS039 and the regioisomer negative
control UBCS060 were synthesized as previously repor-
ted37 and freshly dissolved in dimethylsulfoxide (DMSO)
before any experiment. Chloroquine diphosphate (CQ,
Sigma-Aldrich, C6628) was freshly dissolved in water, N-
acetyl-L-cysteine was freshly dissolved in 12% NaOH 5M
(N-acetyl-L-cysteine (NAC), Sigma-Aldrich, A7250).
3-methyladenine (3-MA, Enzo Life Science, BML-
AP502–0025), Trolox (Sigma-Aldrich, 238813), and
zVAD-fmk (Calbiochem, 627610) were dissolved in
DMSO. For all the experiments, cells were treated with
DMSO as a control.
Western blot
After treatments, cells were collected and lysed in a
buffer containing 50mM Tris-HCl (pH 7.5), 5 mM EDTA,
250mM NaCl, and 0.1% Triton, and completed with
protease (ThermoScientific, A32953) and phosphatase
inhibitors (ThermoScientific, 88667). Total protein
extracts were fractionated by SDS-polyacrylamide gel
electrophoresis, transferred to a nitrocellulose filter, and
subjected to immunoblot assay. Following primary anti-
bodies were used: H3K9Ac (Millipore, 07–352); H3K56Ac
(Abcam, ab76307); SIRT6 (Novus Biologicals, NBP1-
30101); LC3B (Sigma-Aldrich, L7543); total AMP-
activated protein kinase (AMPK; Cell Signaling, 2532)
and phospho AMPK (Thr172; Cell Signaling, 2535); total
(Calbiochem, ST1521) and phospho ULK1 (Ser555 and
Ser757; Cell Signaling, 5869 and 6888 respectively); total
mTOR (Cell Signaling, 4517) and phospho mTOR
(ser2448; Cell Signaling, 2971); Beclin-1 (Cell Signaling,
3738); ATG5 (Cell Signaling, 2630); PARP1 (BD Phar-
mingen, 551025); β-actin (Sigma, A5441); HSP72/73
(Calbiochem, 386032); and H3 (Abcam, ab1791). Fol-
lowing secondary antibodies were used: Goat anti-mouse
or anti-rabbit immunoglobulin G (IgG)-horseradish
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peroxidase conjugated antibodies (Biorad, 1706516 and
1706515 respectively). Densitometry was performed using
ImageJ software.
Immunofluorescence microscopy
HT1080 and H1299 stably expressing EGFP-LC3B or
mRFP-EGFP-LC3B fusion proteins were grown on glass
coverslips, treated with UBCS039, and fixed in 2% for-
maldehyde in phosphate-buffered saline (PBS) 1× for
10min at room temperature. Autophagosome structure
formation was detected observing LC3B puncta in EGFP-
LC3B-expressing cells, while autophagosome maturation
was assessed analyzing yellow- and red-fluorescence
structures in mRFP-EGFP-LC3B (ptf-LC3)-expressing
cells, indicating an accumulation of autophagosomes and
autolysosomes, respectively. Evaluation of autophagosome
structure formation and maturation was performed
independently and in blinded manner by two investigators
counting at least 250 cells for experimental conditions,
cells with more than 10 puncta were considered autop-
hagy positive. Co-localization experiments were per-
formed in H1299 EGFP-LC3B cells stained with primary
antibody against LAMP-2 (H4B4; Santa Cruz Bio-
technology, sc-18822). Anti-Rabbit IgG (Alexa Fluor 555
Conjugate, Cell Signaling, 4413) was used as a secondary
antibody. Preparations were analyzed under an Olympus
AX70 microscope using a ×100/1.35 numerical aperture
objective. Images were acquired using a TCH-1.4ICE
camera (Tucsen, Fujian, China) controlled by ISCapture
and processed using Adobe PhotoShop software (Adobe
Inc., Burlington, NJ, USA).
ATP levels
HeLa cells were treated with 100 µM UBCS039 for 24 h,
detached, and disrupted by three cycles of freezing-
thawing in dry ice with ethanol in a buffer containing
100mM Tris-HCl, pH 7.75, and 4mM EDTA. Lysates
were incubated for 2min at 100 °C and ATP levels mea-
sured by the ATP Bioluminescence Assay Kit CLS II
(Roche Applied Science, 11 699 695 001), according to the
manufacturer instructions, using a microplate lumin-
ometer (PerkinElmer, Waltham, Massachusetts, U.S.).
Obtained values were normalized on total protein amount.
Reactive oxygen species production
Cells were treated with 100 µM UBCS039 for different
times, harvested, washed in PBS 1× and stained for 30 min
at 37 °C with dihydroethidium 50 µM (ThermoScientific
D1168) dissolved in DMEM without fetal bovine serum.
Cells treated with H2O2 5 mM for 30 min were used as a
positive control. About 15 000 events were acquired and
analyzed by using BD Accuri™ C6 flow cytometer (BD
Biosciences, San Diego, CA, U.S.) and gated using forward
scatter and side scatter to exclude cell debris.
Cell proliferation and cell cycle analysis
To test the effect of UBCS039 on cell proliferation,
5 × 104 cells were plated in 60mm Petri dish. After 24 h
from seeding, exponentially growing cells were treated
with the compound at the indicated concentrations for 24,
48, and 72 h. Cells were collected and cell number was
determined by direct counting with hemocytometer.
Progression of cells through cell cycle phases and apop-
tosis were analyzed in both floating and adherent cells by
propidium iodide (PI, BD Biosciences, 556463) and
AnnexinV-fluorescein isothiocyanate (BD Biosciences,
556420)/PI staining respectively, as previously descri-
bed39. All flow cytometric analyses were performed by
using BD Accuri™ C6 flow cytometer (BD Biosciences, San
Diego, CA, U.S.).
Statistics
Experiments were replicated three times and the data
were expressed as mean ± standard deviation or mean ±
standard error. Differences between groups were analyzed
with a two-sided paired or unpaired t test and they were
considered to be statistically significant for *P < 0.05; **P
< 0.01; ***P < 0.001; ****P < 0.0001.
Results
UBCS039 induces deacetylation of SIRT6-targeted histone
H3 sites in human cancer cells
UBCS039 is a newly synthesized pyrrolo[1,2-a]qui-
noxaline derivative, recently described as the first syn-
thetic activator of the NAD+-dependent protein lysine
deacetylase SIRT637. Here we evaluated the effect of
UBCS039 treatment on SIRT6 by analyzing H3 acetyla-
tion levels on K9 and K56 residues (H3K9 and H3K56),
two typical targets of SIRT6 activity. As shown by western
blot analysis in Fig. 1a, UBCS039 induced a time-
dependent deacetylation of histone H3K9 in H1299
non-small cell lung cancer. Pharmacological activation of
SIRT6 by UBCS039 was obtained in several cell lines
regardless of tumor histotype and without affecting SIRT6
protein expression levels (Supplementary 1A, B). In par-
ticular deacetylation of histone H3K9 was found in HeLa
epithelial cervix carcinoma and HCT116 colon carcinoma
lines, while no effect was observed in HT1080 human
fibrosarcoma cell line expressing a higher basal level of
H3K9 histone variant (Supplementary 1A). UBCS039 also
triggered deacetylation of histone H3K56 in HT1080,
while this effect is not appreciable in HeLa and HCT116
cell lines, showing no detectable levels of this histone
post-translational modification.
Interestingly, UBCS060, a pyrrolo[1,2-a]quinoxaline
regioisomer of UBCS039, showing very low SIRT6 affinity
and no effects on SIRT6-dependent deacetylation
in vitro37 failed to stimulate deacetylation of H3K9 and
H3K56 in H1299 cells (Fig. 1b). Moreover, knockdown of
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SIRT6, by increasing in a time dependent manner H3K9
acetylation levels, exerted opposite effects compared to
UBCS039 treatment (Supplementary 1C). Altogether, the
results demonstrated that UBCS039 is a specific activator
of SIRT6 in several human tumor models.
UBCS039 leads to autophagosome accumulation in human
cancer cells
Recent works demonstrate the involvement of SIRT6 in
autophagy in different cellular contexts, including can-
cer21,26,29–31, but specific SIRT6 activators have not been
described yet. Here we investigated the effect of UBCS039
on autophagy signaling and progression. As depicted in
Fig. 2, UBCS039 enhanced, in a time-dependent manner,
LC3B conversion from LC3B form I (18 kDa) to an
autophagosome-associating form, LC3 form II (16 kDa) in
both human H1299 and HeLa cell lines (Fig. 2a, b). By
using H1299 cells stably transfected with EGFP-LC3B
fusion protein, we also found a time-dependent
enhancement of LC3B punctate structure formation
(Fig. 2c), indicative of autophagosome accumulation.
UBCS039-induced autophagosome accumulation was
also observed in HT1080 fibrosarcoma cells stably trans-
fected with EGFP-LC3B fusion protein, thus indicating a
general effect on autophagy upon activation of SIRT6
(Supplementary 2).
Consistent with the lack of deacetylation activity,
H1299 cells exposed to the chemical analog UBCS060
did show neither significant changing in the accumula-
tion of lipidated LC3B protein nor differences in the
percentage of LC3B puncta positive cells (Fig. 3a, b).
More interesting, a significant difference in terms of
UBCS039-induced accumulation of LC3B puncta posi-
tive cells was observed in H1299 SIRT6-depleted cells
when compared to H1299 cells transfected with control
small interfering RNA (Fig. 3c). Finally, UBCS039-
induced autophagic vesicle accumulation was recapitu-
lated by overexpressing the wild-type form of SIRT6
enzyme, but not with the H133Y catalytically inactive
mutant (Fig. 3d), clearly demonstrating that deacetylase
activity of SIRT6 was responsible for autophagosome
accumulation.
Fig. 1 UBCS039 induces deacetylation of SIRT6-targeted histone H3 sites in human H1299 cells. a, bWestern blot analysis of acetylation levels
of histone H3K9 and H3K56 in H1299 human non-small cell lung cancer cell line treated with 75 µM of SIRT6 activator UBCS039 (a) or of the chemical
analog UBCS060 (b) for the indicated times. H3 acetylation levels were quantified by densitometric analyses using ImageJ software and the relative
levels of histone modifications were expressed in the histograms as fold changes of treated versus untreated samples, after H3 normalization. The
results represent mean ± SD of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001
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UBCS039 induces autophagic flux in human cancer cells
Autophagosome accumulation can be indicative of an
increased de novo autophagosome biosynthesis or of an
autophagy inhibition40. To study the effect of UBCS039
on autophagic flux H1299 and HeLa cell lines were
treated with UBCS039 for 24 h in combination or not
with the late-stage inhibitor CQ. As expected, CQ
treatment caused an increase of LC3B conversion from
form I to II, which reflects the basal level of autophagy
of these cells (Fig. 4a, b). This effect was more evident
when cells were exposed to the combination of
UBCS039 and CQ, demonstrating that pharmacological
activation of SIRT6 can induce a complete autophagic
flux in these cells. Notably, autophagy inhibition by the
early-stage autophagy inhibitor 3-MA completely
blocked the effect of UBCS039 treatment on LC3B form
I–II conversion in both H1299 and HeLa cell lines
(Fig. 4a, b). These observations were also strengthened
by fluorescence microscopy experiments performed
in H1299 cells expressing mRFP-EGFP tandem
fluorescence-tagged LC3B construct (ptf-LC3; Fig. 4c).
As expected, the autophagic inhibitor CQ alone or in
combination with UBCS039 caused an extended
increase in the yellow-fluorescence structures, indica-
tive of incomplete impaired autophagosome matura-
tion in lysosomes (autolysosomes). On the contrary,
following UBCS039 treatment an accumulation of both
yellow- and red-fluorescence structures was observed,
indicating an accumulation of both autophagosomes
and autolysosomes, respectively. In line with this
Fig. 2 UBCS039 induces autophagosome accumulation. a, b Western blot analysis of microtubule-associated protein 1 form II (LC3B-II) protein
level in H1299 (a) and HeLa (b) cells treated with 75 µM UBCS039 for the indicated times. LC3B-II levels were quantified by densitometric analyses
using ImageJ software and the relative levels of LC3B-II were expressed in the histograms as fold changes of treated versus untreated samples, after
HSP70 normalization. *P < 0.05; **P < 0.01. S.E. short exposure, L.E. long exposure. c Representative images and relative quantification of fluorescence
microscopic analysis of LC3B puncta positive cells in H1299 EGFP-LC3B treated as indicated in a. Olympus AX70 microscope, ×100 magnification.
Scale bar indicates 10 µm. The results represent the mean ± SEM of three independent experiments. **P < 0.01
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Fig. 3 UBCS060, a chemical inactive analog of UBCS039, fails to deaceylate H3K9 and H3K56 and does not induce autophagosome
accumulation. a Western blot analysis of LC3B-II protein level in H1299 cells treated with 75 µM UBCS060 for the indicated times. LC3B-II levels were
quantified by densitometric analyses using ImageJ software and the relative levels of LC3B-II were expressed in the histograms as fold changes of
treated versus untreated samples, after HSP70 normalization. S.E. short exposure, L.E. long exposure. b Representative images and relative
quantification of fluorescence microscopic analysis of LC3B puncta positive cells in H1299 EGFP-LC3B treated as indicated in a. c Representative
images and relative quantification of fluorescence microscopic analysis of LC3B puncta positive cells in H1299 EGFP-LC3B transiently silenced for
SIRT6 and treated with UBCS039 75 µM for 72 h. Western blot analysis of SIRT6 expression levels. H3 was used as an internal loading control.
d Representative images and relative quantification of fluorescence microscopic analysis of LC3B puncta positive cells in H1299 EGFP-LC3B transiently
transfected with the wild-type (WT) or with the catalytically inactive form of SIRT6 protein (H133Y) for 48 h. Western blot analysis of SIRT6 expression
levels. H3 was used as an internal loading control. b–d Olympus AX70 microscope, ×100 magnification. Scale bar indicates 10 µm. The results
represent mean ± SD of three independent experiments. ***P < 0.001
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evidence, the lysosomal marker LAMP-2 co-localized
with EGFP-LC3 punctate vesicular structures in H1299
EGFP-LC3 cells treated with UBCS039 (Fig. 4d), con-
firming that pharmacological activation of SIRT6 pro-
motes the correct fusion between autophagosomes and
lysosomes.
UBCS039 triggers reactive oxygen species accumulation
and activates the AMPK/ULK1 signaling pathway
A very recent study pointed out a protective role of
SIRT6 in maintaining cardiac homeostasis, demonstrating
that SIRT6 deficiency resulted in decreased oxygen
consumption rate and reduced ATP production41.
Fig. 4 UBCS039 promotes autophagic flux in human cancer cells. a, bWestern blot analysis of LC3B-II protein level in H1299 (a) and HeLa (b) cell
lines treated with 75 µM UBCS039 in combination or not with 3-MA (1 mM) or CQ (25 µM) for 24 h. LC3B-II levels were quantified by densitometric
analyses using ImageJ software and the relative levels of LC3B-II were expressed in the histograms as fold changes of treated versus untreated
samples, after HSP70 normalization. Results represent mean ± SD of three independent experiments. *P < 0.05; ***P < 0.001. c H1299-ptf-LC3 cells
were treated with 75 µM UBCS039 for 72 h or with 25 µM CQ for 24 h alone or in combination. Representative images of fluorescence microscopy
analysis of yellow- and red-fluorescence EGFP-LC3B punctate vesicular structures, indicative of autophagosomes and autolysosomes accumulation,
respectively. d Representative images of co-immunofluorescence analysis of lysosomal marker LAMP-2 and EGFP-LC3B punctate vesicular structures
in H1299 cells expressing EGFP-LC3 treated or not with 75 µM UBCS039 for 72 h. c, d Olympus AX70 microscope, ×100 magnification. Scale bar
indicates 10 µm
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Consistently with this study, we demonstrated that
UBCS039 treatment was effective in promoting intracel-
lular reactive oxygen species (ROS) accumulation in a
time-dependent manner in both H1299 and HeLa cell
lines (Fig. 5a, b). An increase in ATP levels was also
observed after treatment of HeLa cells with UBSC039
(Supplementary 2). Since a link between ROS and
autophagy has been described42,43, HeLa cells were trea-
ted with UBCS039 in combination with NAC or Trolox
antioxidant compounds and LC3B conversion was ana-
lyzed. Our results revealed that NAC and, more effi-
ciently, Trolox impaired LC3B conversion to form II,
indicating that ROS burst has a key role in the upstream
events leading to UBCS039-induced autophagy (Fig. 5c).
Next, we analyzed the impact of UBCS039 on AMPK, a
sensor kinase that is activated by changes in ATP levels or
oxidative stress, which in turn, can inhibit the mTOR
pathway and/or activate the ULK1 protein complex,
responsible for the initiation step of autophagy44. As
shown in Fig. 5d, UBCS039 treatment increased AMPK
phosphorylation at Thr172, decreased the mTOR phos-
phorylation at Ser2448, and concomitantly induced the
activation of ULK1. In particular, we found increased
ULK1 phosphorylation levels at Ser555 (active ULK1
form) and no alteration at Ser757 (inactive ULK1 form).
Moreover, the ULK1-regulated ATG proteins Beclin-1
and ATG5, required for phagophore formation and
elongation, mediated the autophagy cascade. Notably,
UBCS039 treatment increased AMPK phosphorylation
also in H1299 cells, and most remarkably, pretreatment of
cells with Trolox partially counteracted the effect of
UBCS039 on AMPK signaling pathway (Supplemen-
tary 3B). Overall, these results demonstrate that phar-
macological activation of SIRT6 induces autophagy by
ROS-mediated AMPK/ULK1 pathway activation.
UBCS039 induces autophagy-associated cell death
In cancer, it is still unclear if autophagy may promote
cell death or cause chemoresistance. Therefore, in order
to analyze the consequence of UBCS039-induced autop-
hagy activation, the impact of SIRT6 activator on cell
growth was exploited. To this aim, we analyzed the pro-
liferation rate of cancer cells exposed to different doses of
the SIRT6 activator UBCS039 or the chemical inactive
analog UBCS060. As shown in Fig. 6a, UBCS039 led to a
strong decrease of cell proliferation in a dose-dependent
manner when compared with control or DMSO-treated
cells, starting from day 3 of growth (48 h after treatment)
in both H1299 and HeLa cell lines. By contrast, no sig-
nificant effect on cell proliferation was observed in cells
exposed the chemical analog UBCS060 (Fig. 6a). More-
over, UBCS039-induced cell growth inhibition was of
general application because it was observed also in other
tumor cell lines (Supplementary 4A).
Successively, we investigated if cell growth inhibition
was associated with apoptosis induction. Flow cytometric
analysis of AnnexinV staining in both H1299 and HeLa
cells demonstrated the ability of UBCS039 to induce
apoptosis (Fig. 6b). These results were also corroborated
by the analysis of sub-G1 peak of cell cycle distribution
and by western blot analysis of PARP1 cleaved form
(Supplementary 4B–D). Interestingly, exposure of cells to
zVAD-fmk, a pan-caspase inhibitor, was able to revert
UBCS039 effect on apoptosis (Fig. 6b). Moreover, expo-
sure of cells to the autophagy inhibitor CQ reduced (of
about 50%) the apoptotic effect of UBCS039 (Fig. 6b),
indicating an involvement of autophagy in UBCS039-
mediated apoptosis. Finally, the role of SIRT6 on
autophagy-mediated cell death was corroborated by a
genetic approach demonstrating that overexpression of
wild-type, but not the catalytic inactive form of SIRT6 was
able to increase cell death that was reverted by CQ
treatment (Fig. 6c). Taken together, these results clearly
demonstrate that pharmacological activation of SIRT6
triggers an increase of autophagy that results in apoptosis
in different human cancer cells.
Discussion
SIRT6 involvement in autophagy has recently been
reported in different cell contexts, including cancer21,32,45.
Of note, all the experiments have been performed by
using genetic approaches, while no pharmacological
modulation of SIRT6 activity have been described. Here
we demonstrate that a newly synthesized SIRT6 activator,
the pyrrolo[1,2-a]quinoxaline derivative UBCS039, is
effective in triggering autophagy in several human cancer
cell lines of different histotypes. The results reported here
indicate that UBCS039 is specific for SIRT6 deacetylase
activity because: (i) UBCS039, but not a chemical analog,
increases SIRT6 specific activity on target histone in cells;
(ii) UBCS039 is not able to induce autophagy in SIRT6-
depleted cells; and (iii) overexpression of wild-type SIRT6,
but not of its catalytically inactive mutant, exerts the same
effect of UBCS039 on autophagy. UBCS039-specific
activity for SIRT6 is further supported by our previous
study demonstrating no significant activation of SIRT1,
SIRT2, and SIRT3 deacetylase activity by UBCS039 in
enzymatic assays37. Even though UBCS039 is also able to
enhance SIRT5 desuccinylase activity in vitro37, pharma-
cological or genetic inactivation of SIRT5 was reported to
increase autophagy24, further supporting that the effects
of UBCS039 on autophagy is not related to its effect on
SIRT5 but are dependent on its ability to activate SIRT6.
Even though our studies reveal for the first time that
activation of SIRT6 activity by UBCS039 induces deace-
tylation of SIRT6-targeted histone H3 sites, we noted
difference in UBCS039-mediated H3K9 and H3K56 dea-
cetylation among cell lines. This differential effect may
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Fig. 5 UBCS039 induces autophagy via AMP-activated protein kinase (AMPK) signaling pathway activation. a, b Representative experiment
of flow cytometric analysis of ROS production by DHE staining in H1299 (a) and HeLa (b) cell lines treated with 100 µM UBCS039 for the indicated times.
ROS production was expressed in the histograms as percentage of cells positive for DHE staining. Results represent mean ± SD of three independent
experiments. ***P < 0.001. cWestern blot analysis of LC3B-II protein levels in HeLa cells treated with 100 µM UBCS039 in combination or not with antioxidant
compounds NAC (5mM) and Trolox (200 µM) for the indicated times. LC3B-II levels were quantified by densitometric analyses using ImageJ software and
the relative levels of LC3B-II were expressed in the histograms as fold changes of treated versus untreated samples, after β-actin normalization. Results
represent mean ± SD of three independent experiments. **P < 0.01; ***P< 0.001; ****P< 0.0001. d Western blot analysis of the indicated proteins in HeLa
cells treated with 100 µM UBCS039 for the indicated times. Total AMPK, total ULK1, total mTOR, and HSP70 were used as internal loading controls
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Fig. 6 UBCS039 leads to autophagy-mediated apoptosis. a In vitro growth curves of H1299 and HeLa cell lines treated or not with UBCS039 or
UBCS060 at the indicated doses. In all, 5 × 104 cells were seeded at day 0 and treated at day 1. The figure represents mean ± SD of three independent
experiments. b Representative experiment of flow cytometric analysis of AnnexinV-positive cells in H1299 and HeLa cell lines treated with 100 µM
UBCS039 for 72 h in combination or not with pan-caspase inhibitor zVAD-fmk (50 μM) or the late-stage autophagy inhibitor CQ (25 μM). The results
represent mean ± SD of three independent experiments. c Representative experiment of flow cytometric analysis of AnnexinV-positive cells in HeLa
human epithelial cervix carcinoma cell lines transiently transfected with the empty vector (SCR) and with the wild-type (WT) or the catalytically
inactive form of SIRT6 protein (H133Y) for 72 h. The results represent mean ± SD of three independent experiments. *P < 0.05; **P < 0.01
Iachettini et al. Cell Death and Disease  (2018) 9:996 Page 10 of 12
Official journal of the Cell Death Differentiation Association
depend on the disparate levels of basal acetylation at H3,
as well as on the difference in HAT or HDAC enzymes
that have H3K9 or K56 as their substrate.
By using both biochemical and imaging approaches, we
reported that the autophagic flux was increased upon
UBCS039-mediated SIRT6 activation, as evidenced by
canonical conversion of LC3B-I into LC3B-II as well as
autophagosome formation and maturation. Digging dee-
per into the mechanisms by which pharmacological acti-
vation of SIRT6 induces autophagy, we found increased
intracellular ROS levels, a well-established inducer of the
autophagic process42,43. Interestingly, antioxidants were
able to completely counteract UBCS039-induced autop-
hagy, confirming that ROS burst had a key role in the
upstream events leading to autophagy commitment. Even
though the molecular mechanisms linking increased ROS
production and SIRT6 activation were not investigated in
the present work, we can speculate that the increased
activity of SIRT6 requires NAD+, mainly produced at
the level of mitochondrial electron transport chain.
The increased ATP level upon SIRT6 activation states for
increased NADH oxidation and nicely correlates with
increased ROS production. Moreover, it is reported that
overexpression of SIRT6 results in increased ROS pro-
duction and that a specific miR-33a by suppressing SIRT6
induced tumor growth through oxidative stress resis-
tance46. Work is in progress in our laboratory in order to
fill this gap.
Sirtuins and AMPK are cellular energy sensors and their
function and regulation are closely intertwined1,47. So far,
little is known about the link between SIRT6 and AMPK
in cancer. It has been reported that SIRT6 overexpression
can activate the AMPK pathway by elevating the AMP/
ATP ratio48,49. Nevertheless, our results revealed
increased ATP levels and AMPK activation upon
UBCS039-mediated SIRT6 activation. This apparent
contradiction could be explained by the fact that, as
already reported50, AMPK is a redox sensitive enzyme
that is activated by ROS flux. We also demonstrated that
UBCS039-mediated SIRT6 activation promotes the for-
mation of phagophores by the activation of AMPK-
mTOR-ULK axis. Indeed, UBCS039 decreases mTOR
phosphorylation at Ser2448 and increases ULK1 phos-
phorylation at Ser555, leading to an increase of ULK1-
regulated ATG proteins, such as Beclin-1 and Atg5.
Nevertheless, we cannot exclude that SIRT6 may also act
deacetylating autophagy-related molecules involved in
later stages, thus inducing other non-canonical pathway
of autophagy. For example, Atg7, Atg8, and Atg12 have
been reported to be acetylated and Atg protein acetylation
can either promote or inhibit their function in
autophagy28.
Our study also reports the cellular consequences of
autophagy induction by the pharmacological activation of
SIRT6, demonstrating that UBCS039 limits the growth of
several cancer cell lines by eliciting apoptosis. The
crosstalk between autophagy and apoptosis was directly
assessed by showing that: (i) the inactive compound
UBCS060, unable to both activate SIRT6 and induce
autophagy, failed to reduce cancer cell growth; and (ii) the
CQ chemical inhibitor of autophagy partially reverts
UBCS039 effects on apoptosis. Of note, since the pan-
caspase inhibitor zVAD-fmk completely reverts apoptosis
induced by UBCS039, we cannot exclude an autophagy-
independent UBCS039-mediated cell death.
Autophagy and its relationship with apoptosis in cancer
has been widely studied and now it is well known that
autophagy can either suppress or activate cell death34,51,52.
Our results strongly indicate that an excessive stimulation
of autophagy can be lethal for cancer cells with different
apoptotic thresholds and genetic background.
Overall, our results give a preclinical proof of concept
that the direct pharmacological activation of SIRT6
results in autophagy induction, providing a strong ratio-
nale for the development of innovative anticancer (com-
bined) therapies based on activation of sirtuins.
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